Trulieve Cannabis Corp. — Q3 2026 Form 10-Q
Reporting period: Three and nine months ended September 30, 2026. Amounts below are in U.S. dollars; financial statement amounts are in millions unless noted. The company is a vertically integrated medical-cannabis operator with 208 dispensaries across Florida, Pennsylvania, West Virginia and Georgia. Comparisons with 2025 are affected by the June 3, 2026 deconsolidation of Harvest.
Financial performance and liquidity
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | $230.2 | $288.2 | $787.9 | $888.0 |
| Gross profit / margin | $148.0 / 64.3% | $169.9 / 58.9% | $480.4 / 61.0% | $536.0 / 60.4% |
| Operating income (loss) | $42.5 | $42.2 | $(292.3) | $128.2 |
| Net income (loss) | $0.8 | $(28.8) | $(403.0) | $(78.7) |
| Adjusted EBITDA (non-GAAP) | $89.2 | $102.7 | $287.6 | $322.5 |
| Cash provided by operating activities | Not stated for quarter | Not stated for quarter | $183.3 | $213.6 |
Q3 revenue fell 20% year over year, principally because Harvest was no longer consolidated; management said revenue excluding that effect increased, led by Georgia and Pennsylvania. Nine-month revenue declined 11%, reflecting deconsolidation and pricing pressure in some mature markets, partly offset by growth in Georgia. Management said revenue trends improved sequentially through Q3.
Q3 gross margin improved to 64.3%, while SG&A was $87.8 million, or 38.2% of revenue versus 34.4% a year earlier. Management attributed the higher SG&A ratio mainly to market mix and a smaller revenue base after deconsolidation. Nine-month gross margin was 61.0%; SG&A was 37.4% of revenue.
The nine-month net loss includes a $403.3 million, primarily non-cash, loss on deconsolidating Harvest. Adjusted EBITDA excludes this charge and other adjustments and is not a GAAP measure or a measure of cash available for discretionary spending.
Cash and cash equivalents were $326.7 million at September 30, 2026, versus $255.5 million at year-end 2025. Nine-month investing cash outflow was $156.8 million, including $58.4 million of cash disposed in the Harvest transaction, $63.5 million of capital expenditures and a $40.0 million intellectual-property license payment. Financing activities provided $44.7 million, including long-term borrowing proceeds. Management believes existing cash will cover anticipated needs for at least 12 months.
At quarter-end, private placement notes were $200.0 million principal, with a 10.5% stated rate and December 2030 maturity. Notes payable totaled $93.8 million principal; construction finance liabilities were $120.9 million. The company reported compliance with borrowing covenants. On October 7, 2026, it repaid approximately $65.1 million of mortgage debt and terminated the related interest-rate swap.
Material developments, outlook and risks
- Harvest deconsolidation: The company retained an equity-method investment, carried at $146.1 million at quarter-end, and recognized $9.7 million of its loss for the nine-month period. Harvest’s results are no longer consolidated after June 3, making period comparisons less direct. The company’s maximum exposure associated with Harvest, including its management-services receivable, was $167.3 million.
- Taxes: The nine-month tax provision was $70.1 million despite a pre-tax loss. Uncertain tax position liabilities were $625.4 million, including $610.0 million related to the company’s IRC Section 280E position and $104.8 million of accrued interest. The company disputes IRS proposed assessments for earlier years; proposed penalties of about $38.1 million are not included in that liability. Management says it will contest the penalties. The company’s tax treatment relies on legal and regulatory developments and remains subject to examinations and judgment.
- Regulatory outlook: Following the April 2026 federal rescheduling of medical cannabis to Schedule III, the company applied for DEA registrations in its operating states. It reported that applications were included in the DEA’s October list, inspections were substantially completed, and registrations had been received for substantially all dispensaries as of filing. Texas expansion remains subject to final licensing and regulatory approval.
- Growth and capital allocation: The company acquired perpetual, royalty-free Alien Labs and Connected brand rights for Florida and Texas for $40.0 million plus approximately $0.4 million of qualifying costs. It expects expansion to support revenue growth, subject to Texas approvals. A share-repurchase authorization of up to $50.0 million or 8,495,038 shares runs through June 16, 2027; no repurchases had occurred by September 30.
- Key risks: Cannabis licensing and regulatory changes, competition and pricing pressure, restricted financial services, and the uncertain, potentially volatile valuation of the Harvest investment. The filing also identifies substantial tax uncertainty. No material lawsuits were reported aside from the IRS dispute; $0.3 million was accrued for other pending claims.
The filing provides no formal numeric revenue or earnings guidance. Management’s outlook is conditional on licensing, operational performance and market conditions; forward-looking statements are not guarantees.
Important facts for investors to verify
- How much of reported revenue decline reflects Harvest deconsolidation versus underlying sales, pricing and market trends.
- Whether Harvest’s results, valuation and $21.3 million management-services receivable support the carrying value and the company’s stated exposure.
- Developments in the IRC Section 280E dispute, IRS examinations, accrued interest and potential penalties.
- Cash generation and liquidity after the October $65.1 million debt repayment, alongside upcoming debt, lease and construction-finance obligations.
- Progress on DEA registrations, Texas final licensure, and any resulting changes to operations or expansion plans.